MULTIPLE MYELOMA

Latest News

November 6th 2018

Elotuzumab Triplet Approved by FDA for Treatment of Myeloma

Based on data from the phase II ELOQUENT-3 trial, elotuzumab (Empliciti) has received approval from the FDA in combination with pomalidomide (Pomalyst) and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor.

November 5th 2018

Armored CAR T Cells in Multiple Myeloma

By Eric Smith, MD, PhD

October 31st 2018

Daratumumab Added to Lenalidomide and Dexamethasone Improves Survival in Frontline Myeloma

By Jason M. Broderick

October 9th 2018

Causes for Relapse in Multiple Myeloma With CAR T cells

By Eric Smith, MD, PhD

October 7th 2018

Selinexor Granted Priority Review by FDA for Multiple Myeloma

By Targeted Oncology Staff

Latest Videos

$Anti-BCMA Therapy for Relapsed and Refractory Multiple Myeloma$

Anti-BCMA Therapy for Relapsed and Refractory Multiple Myeloma

Factors To Be Considered When Treating RRMM

Progress in the Treatment of R/R Myeloma

$Targeting CD38 in Relapsed/Refractory Multiple Myeloma$

Targeting CD38 in Relapsed/Refractory Multiple Myeloma

Emerging BCMA-directed CAR T-Cell Therapies in RRMM

Case 4: Treatment Considerations for High-Risk and Standard-Risk R/R Myeloma

$Case 4: Relapsed-Refractory Myeloma$

Case 4: Relapsed-Refractory Myeloma

Case 3: Treatment Considerations for Elderly Patients With Myeloma

Case 3: Geriatric Assessment in Myeloma

Case 3: An Elderly Patient With Newly Diagnosed Myeloma

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

43rd Annual Miami Breast Cancer Conference®

Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; Hope S. Rugo, MD, FASCO

Multimedia

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Multimedia

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Multimedia

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Multimedia

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Multimedia

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

More News

Targeted Top 5: Oncology News This Week

ByDanielle Ternyila

October 5th 2018

Infographic: Here, we share the top 5 oncology news stories we reported this week, including the most recent FDA updates and expert insights on key developments in the field.

FDA Approves NGS Assay to Detect MRD in ALL, Multiple Myeloma

ByJason Harris

October 2nd 2018

The next-generation sequencing assay clonoSEQ has gained FDA approval as a test for minimal residual disease in patients with acute lymphoblastic leukemia or multiple myeloma.

Once-Weekly Carfilzomib Regimen Approved by the FDA for Myeloma

ByJason M. Broderick

October 1st 2018

A once-weekly dosing option of carfilzomib (Kyprolis) has been approved by the FDA for use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma, Amgen, the manufacturer of the agent, has announced.<br />  

Immunotherapy Combination Treatment Options Growing in R/R Multiple Myeloma Space

BySamantha Hitchcock

September 25th 2018

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, for patients with relapsed/refractory multiple myeloma, as well as emerging immunotherapy treatment options.

Case 4: BCMA-Targeted CAR T-Cell Therapy in Myeloma

September 25th 2018

Case 4: CAR T-Cell Therapy in Myeloma

September 25th 2018

Case 4: Molecular Testing and CAR T-Cell Therapy in Myeloma

September 25th 2018

Case 4: CAR T-Cell Therapy for Heavily Pretreated Myeloma

September 25th 2018

Case 3: Treatment for Relapsed Myeloma with 17p Deletion

September 25th 2018

Case 3: Molecular Testing in Relapsed Myeloma

September 25th 2018

Case 3: Aggressive Relapse of Multiple Myeloma

September 25th 2018

Case 2: Evolution of Molecular Testing in Myeloma

September 25th 2018

Case 2: MRD Negativity in High-Risk Myeloma

September 25th 2018

Case 2: Molecular Risk Stratification in Myeloma

September 25th 2018

Case 2: The Role of Maintenance Therapy in Myeloma

September 25th 2018

Case 1: Transplant Eligibility in Myeloma

September 25th 2018

Case 1: Consolidation Therapy in Myeloma

September 25th 2018

Case 1: Molecular Testing in Myeloma

September 25th 2018

Case 1: Ineligibility for Transplant in Myeloma

September 25th 2018

Case 1: Optimal Induction Therapy for Myeloma

September 25th 2018

Management of Multiple Myeloma

September 25th 2018

Targeted Oncology Launches its Latest Virtual Tumor Board on Multiple Myeloma

September 20th 2018

<em>Targeted Oncology</em>™ will launch its third “Expert Perspective: Virtual Tumor Board” on Monday, September 24. Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.

Selinexor/Dexamethasone Combo Shows Promising Activity in Penta-Refractory Myeloma

ByJason Harris

September 15th 2018

The combination of selinexor and dexamethasone induced an overall response rate of 26.2% and a median overall survival of 8.6 months in patients with penta-refractory multiple myeloma, according to phase IIb results presented at the 2018 SOHO Annual Meeting.

Safety of Carfilzomib Combinations Confirmed in Multiple Myeloma

September 14th 2018

Consistent benefit was seen with carfilzomib (Kyprolis)-based regimens across subgroups of patients with multiple myeloma in the ASPIRE and ENDEAVOR trials, according to updated safety data reported at the 2018 SOHO Annual Meeting.

Convenience of Oral Regimen for the Treatment of MM

September 10th 2018